Ventilatory performance of AMBU® AuraGain™ and LMA® Supreme™ in laparoscopic surgery: A randomised controlled trial
- PMID: 34550812
- DOI: 10.1177/0310057X211030521
Ventilatory performance of AMBU® AuraGain™ and LMA® Supreme™ in laparoscopic surgery: A randomised controlled trial
Abstract
The Ambu® AuraGain™ (Ambu A/S, Ballerup, Denmark) is a newer phthalate-free, single-use supraglottic device with the advantage of a facility for tracheal intubation if necessary intraoperatively. We compared the oropharyngeal leak pressures and other performance variables between the AMBU AuraGain and the LMA® Supreme™ (Teleflex Medical, Athlone, Co. Westmeath, Ireland) in patients undergoing laparoscopic cholecystectomy and preperitoneoscopic inguinal herniorrhaphy with carbon dioxide insufflation under controlled ventilation. We recruited 120 American Society of Anesthesiologists physical status class I-3 patients between the ages of 21 and 80 years undergoing laparoscopic cholecystectomy or preperitoneoscopic inguinal herniorrhaphy into this single-centre randomised controlled trial. The primary outcome measure was the oropharyngeal leak pressures. Secondary outcomes included insertion parameters, ventilatory characteristics and postoperative sequelae. The AuraGain had slightly but significantly higher oropharyngeal leak pressures than the LMA Supreme (mean (standard deviation) 26.1 (6.9) versus 21.4
Keywords: AuraGain; LMA Supreme; Supraglottic device; laparoscopic surgery.
Similar articles
-
Ambu® AuraGain™ versus LMA Supreme™ Second Seal™: a randomised controlled trial comparing oropharyngeal leak pressures and gastric drain functionality in spontaneously breathing patients.Anaesth Intensive Care. 2017 Mar;45(2):244-250. doi: 10.1177/0310057X1704500215. Anaesth Intensive Care. 2017. PMID: 28267947 Clinical Trial.
-
A randomized comparison of the Ambu AuraGain versus the LMA supreme in patients undergoing gynaecologic laparoscopic surgery.J Clin Monit Comput. 2017 Dec;31(6):1255-1262. doi: 10.1007/s10877-016-9963-0. Epub 2016 Nov 26. J Clin Monit Comput. 2017. PMID: 27889843 Clinical Trial.
-
Comparison of oropharyngeal leak pressure between the Ambu® AuraGain™ and the LMA® Supreme™ supraglottic airways: a randomized-controlled trial.Can J Anaesth. 2018 Jul;65(7):797-805. doi: 10.1007/s12630-018-1120-4. Epub 2018 Mar 26. Can J Anaesth. 2018. PMID: 29582360 Clinical Trial. English.
-
Brief review: The LMA Supreme™ supraglottic airway.Can J Anaesth. 2012 May;59(5):483-93. doi: 10.1007/s12630-012-9673-0. Epub 2012 Feb 9. Can J Anaesth. 2012. PMID: 22318376 Review.
-
Role of laryngeal mask airway in laparoscopic cholecystectomy.World J Gastrointest Surg. 2015 Nov 27;7(11):319-25. doi: 10.4240/wjgs.v7.i11.319. World J Gastrointest Surg. 2015. PMID: 26649155 Free PMC article. Review.
Cited by
-
Choice of supraglottic airway devices: a network meta-analysis of randomised controlled trials.Br J Anaesth. 2024 Dec;133(6):1284-1306. doi: 10.1016/j.bja.2024.09.001. Epub 2024 Oct 15. Br J Anaesth. 2024. PMID: 39406569
-
Comparison of oropharyngeal leak pressure and insertion characteristics of Ambu AuraGain and i-gel in patients undergoing laparoscopic inguinal hernia repair: A randomized control trial.J Anaesthesiol Clin Pharmacol. 2025 Jul-Sep;41(3):516-522. doi: 10.4103/joacp.joacp_439_24. Epub 2025 Jun 19. J Anaesthesiol Clin Pharmacol. 2025. PMID: 40635825 Free PMC article.
-
Effect of the new video laryngeal mask airway SaCoVLM on airway management in lateral laparoscopic urological surgery: A single center randomized controlled trial.Sci Rep. 2024 Jan 25;14(1):2132. doi: 10.1038/s41598-024-51856-4. Sci Rep. 2024. PMID: 38272937 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources